Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Dicerna's DCR-PHXC reduces urinary oxalate levels in Phase I

September 14, 2018 1:05 PM UTC

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) reported interim six-week data from the Phase I PHYOX trial showing that single subcutaneous doses of DCR-PHXC brought urinary oxalate levels into the normal or near-normal range in five of eight evaluable patients with primary hyperoxaluria. All eight patients achieved a >30% reduction in urinary oxalate levels from baseline. DCR-PHXC was well tolerated. The company plans to present detailed data from PHYOX in 4Q18.

Dicerna’s lead programs are designed to silence disease-driving genes in the liver and are based on the company's GalXC technology, which allows attachment of N-acetylgalactosamine sugars to the extended region of RNAi molecules. DCR-PHXC is a subcutaneously delivered RNAi-based therapeutic using GalXC that selectively silences lactate dehydrogenase A (LDHA) in the liver...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Dicerna Pharmaceuticals Inc.

BCIQ Target Profiles

Lactate dehydrogenase A (LDHA)